Skip to main content
. 2004 Jul 23;5(8):825–830. doi: 10.1038/sj.embor.7400205

Figure 1.

Figure 1

The supernatants of necrotic cells that cause dendritic cell maturation contain HMGB1. (A) The expression of the CD83 and CD86 surface molecules was assessed by flow cytometry on untreated immature human DCs or DCs challenged with freeze/thawed (F/T) HeLa and polymorphonuclear cells (PMNs) or with their supernatants (sup). Only DCs treated with necrotic HeLa cells or their supernatants had significantly higher expression of the markers (P<0.001). (B) The intracellular distribution of HMGB1 was assessed by immunohistochemistry in PMNs and HeLa cells. Nuclei were revealed by staining with DAPI. (C) HLA-DR, CD40, CD83 and CD86 surface molecules were assessed by flow cytometry on immature DCs untreated or treated with the supernatant of necrotic HeLa cells (F/T sup) in the absence or in the presence of anti-HMGB1 antibodies (Ab), of irrelevant control antibodies or the HMGB1 inhibitory fragment box A. Results are expressed as relative increase (y-axis) in surface expression. DCs treated with F/T sup and anti-HMGB1 antibodies had significantly lower expression of the markers (*P<0.005). Experiments were repeated at least three times with DCs from different donors. (D) HMGB1 was assessed by western blotting in the pellet (P) or in the supernatant (S) of necrotic F/T HeLa or PMNs. As a control, purified recombinant HMGB1 (rHMGB1; 10, 50 or 100 ng/lane) was used.